Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

1127421

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bacterial Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 14 May (HL15384), what assessment they have made of the number of people, with or without resistant blood stream infections, who have Carbapenem resistant E. coli-like bacteria present in their bodies; and what (1) proposed, and (2) current, initiatives there are to control the transmission of such bacteria.
tabling member printed	Baroness Gardner of Parkes
uin	HL15832
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>The 2018 English surveillance programme for antimicrobial utilisation and resistance report contains information on carbapenem-resistant Escherichia coli (E. coli) causing bloodstream infections in England. In 2017 there were 18 cases. The number of people with other infections and carriage of E. coli resistant to carbapenems is harder to ascertain as surveillance is not as uniform.</p><p>Public Health England (PHE) publishes guidance on the prevention and control of carbapenemase-producing Enterobacteriaceae (including E. coli); guidance is available for both acute and non-acute settings, copies of the <em>Toolkit for managing carbapenemase-producing Enterobacteriaceae in non-acute and community settings</em> and <em>Acute trust toolkit for the early detection, management and control of carbapenemase-producing Enterobacteriaceae</em> are attached. PHE is supporting actions outlined in the United Kingdom’s Tackling Antimicrobial Resistance National Action Plan that aim to prevent and control the transmission of carbapenem-resistant bacteria, which includes reducing the number of specific drug-resistant infections in people by 10% by 2025; reducing UK antimicrobial use in humans by 15% by 2024; and adding carbapenem-resistant Gram-negative infections to the list of notifiable diseases in existing laboratory reporting systems.</p> answering member printed Baroness Blackwood of North Oxford attachment 1 file name Acute_trust_toolkit_for_the_early_detection.pdf title Acute trust toolkit 2 file name CPE-Non-AcuteToolkit_CORE.pdf title CPE Non Acute toolkit question first answered 04/06/2019 13:45:10 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3596 label Biography information for Baroness Gardner of Parkes

1127424

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the potential of schemes by pharmaceutical companies to develop recycling and recovery schemes for respiratory inhalers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL15835
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>We are informed by NHS England that its joint Public Health England funded Sustainable Development Unit (SDU) has reviewed a scheme operated by GlaxoSmithKline that encourages return of inhalers for recycling. The scheme is very welcome but limited in scope, currently recovering around 1% of all inhalers.</p><p>All used inhalers can already be returned to all pharmacies to be disposed of by incineration with the medicines waste streams.</p><p>NHS England has invited industry suggestions to the national Low Carbon Inhalers Working Group established by the SDU, on ways to increase recovery for environmentally safe disposal and recycling.</p> answering member printed Baroness Blackwood of North Oxford question first answered 04/06/2019 13:46:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1127426

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the impact of the use of metred dose inflators containing hydrofluorocarbons in releasing greenhouse gases.
tabling member printed	Lord Hunt of Kings Heath
uin	HL15837
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>We have made no such assessment on the proportion of the National Health Service carbon footprint made by hydrofluorocarbon in metred dose inhalers or of the impact of the use of metred dose inhalers containing hydrofluorocarbons in releasing greenhouse gases. However, we are informed by NHS England that the National Atmospheric Emissions Inventory calculated the carbon emissions from inhalers in England as 850,000 tonnes of carbon dioxide equivalents. This is equivalent to approximately 4% of the entire carbon footprint of the NHS in England.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15840 question first answered 04/06/2019 13:46:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1127427

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they intend to have, if any, with pharmaceutical companies about how the environmental damage caused by asthma inhalers may be reduced.
tabling member printed	Lord Hunt of Kings Heath
uin	HL15838
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>NHS England has been in regular dialogue with industry over the last 18 months about the need to reduce the environmental damage caused by asthma inhalers. As a result, an industry working group on this has been formed, chaired by the Industry Pharmaceutical Aerosol Consortium (IPAC). IPAC has now accepted an invitation to join the national Low Carbon Inhalers Working Group, chaired by the Sustainable Development Unit, to represent industry. This working group has been asked to provide proposals from industry on reducing the carbon impacts of inhalers to support the NHS Long Term Plan target.</p> answering member printed Baroness Blackwood of North Oxford question first answered 04/06/2019 13:39:39 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1127428

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the sufficiency of the progress made by NICE on working with clinicians and industry to promote greater use of asthma inhalers with low global warming potential.
tabling member printed	Lord Hunt of Kings Heath
uin	HL15839
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) published an online only patient decision aid for inhalers used in the treatment of asthma on 8 April 2019.</p><p>The purpose of this aid is to help people with asthma and their healthcare professional to discuss the different inhaler devices that are available to treat their condition and where appropriate, to consider the environmental impact of the inhaler. The patient decision aid has been downloaded over 1,500 times since its publication.</p><p>To encourage use of the decision aid, NICE is contributing to an expert working group on sustainable inhalers led by the Sustainable Development Unit which is actively promoting this work. The working group members include clinicians and patient organisations, such as Asthma UK and the British Lung Foundation. NICE has also shared the patient decision aid through its network of NICE associates - a network of National Health Service professionals who support implementation of NICE guidance across the NHS.</p> answering member printed Baroness Blackwood of North Oxford question first answered 04/06/2019 13:42:39 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1127429

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the proportion of the NHS carbon footprint made by hydrofluorocarbon in metred dose inflators.
tabling member printed	Lord Hunt of Kings Heath
uin	HL15840
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>We have made no such assessment on the proportion of the National Health Service carbon footprint made by hydrofluorocarbon in metred dose inhalers or of the impact of the use of metred dose inhalers containing hydrofluorocarbons in releasing greenhouse gases. However, we are informed by NHS England that the National Atmospheric Emissions Inventory calculated the carbon emissions from inhalers in England as 850,000 tonnes of carbon dioxide equivalents. This is equivalent to approximately 4% of the entire carbon footprint of the NHS in England.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15837 question first answered 04/06/2019 13:46:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1127468

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of (a) school nurses and (b) health visitors.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	256319
answer	answer is ministerial correction date of answer 23/05/2019 answer text <p>From April 2013, local authorities have been responsible for public health locally, including commissioning public health services for school aged children in their areas. In October 2015 responsibility for zero to five commissioning was also transferred to local authorities.</p><p>It is therefore for local authorities to assess the health needs of their populations and commission the appropriate health visiting and school nursing services and workforce, based around local needs.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 23/05/2019 16:45:18 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1127486

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Brexit
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many officials in his Department have been seconded away from their normal duties to work on the UK's withdrawal from the EU; and what effect that secondment of staff has had on the effectiveness of his Department.
tabling member constituency	Tottenham
tabling member printed	Mr David Lammy
uin	256204
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>The number of individuals who have been transferred or seconded to work in preparations for the United Kingdom to leave the European Union in other Government departments is not recorded.</p><p>Across the Department, staff are working on a range of policy areas related to EU Exit. Communications, analytical and legal staff also provide advice as required. Staff may have been redistributed within their directorates to support or undertake work which involves preparations for EU Exit. Officials may also have reprioritised their work to include EU Exit work, whilst remaining in their primary roles.</p><p>The Department is continually reviewing workforce plans, reprioritising and assessing changing needs, including identification and cessation of non-priority work where appropriate. The Civil Service as a whole is working to ensure that EU Exit implementation is carried out to a high standard, without impacting public service delivery across the whole of Government.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 29/05/2019 13:40:43 answering member 1585 label Biography information for Stephen Hammond
tabling member	206 label Biography information for Mr David Lammy

1127499

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256254
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256255 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1127500

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256255
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256254 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper